Brainstorm Cell Therapeutics Inc banner

Company Overview

Business Description

Sector
Health Care
Industry
Biotechnology
Headquarters
United States of America US
Employees
23
IPO date
May 28, 2003

Brainstorm Cell Therapeutics, Inc. is a biotechnology company, which develops and commercializes autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis, Progressive Multiple Sclerosis, Alzheimer's disease, and other neurodegenerative diseases. The company is headquartered in New York City, New York and currently employs 20 full-time employees. The company went IPO on 2003-05-28. The firm is in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease; progressive multiple sclerosis (PMS); Alzheimer’s disease (AD); and other neurodegenerative diseases. Its NurOwn, a cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived MSCs to secrete high levels of neurotrophic factors (NTFs), modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. The company has completed a Phase III pivotal trial in ALS (NCT03280056); this trial investigated the safety and efficacy of repeat-administration of autologous MSC-NTF cells. The firm's wholly owned subsidiary, Brainstorm Cell Therapeutics Ltd. holds exclusive rights to commercialize NurOwn technology.

Brainstorm Cell Therapeutics Inc Investor Relations

Address
1325 Avenue Of Americas, 28th Floor
New York City, New York
United States of America

Management

Mr. Chaim Lebovits

President & CEO

Biography unavailable

Dr. Irit Arbel DSc, Ph.D.

Co-Founder & Independent Vice Chair of the Board

Biography unavailable

Ms. Alla Patlis CPA, M.B.A.

Interim CFO & Controller

Biography unavailable

Mr. Uri Yablonka

Executive VP, Chief Business Officer, Secretary & Director

Biography unavailable

Dr. Hartoun Hartounian Ph.D.

Executive VP & COO

Biography unavailable

Dr. Daniel Offen Ph.D.

Chief Scientific Advisor

Biography unavailable

Ms. Mary Kay Turner

Senior Vice President of Patient Advocacy & Government Affairs

Biography unavailable

Dr. Ibrahim Dagher M.D.

Executive VP & Chief Medical Officer

Biography unavailable

Dr. Netta Blondheim-Shraga Ph.D.

Senior Vice President of Research and Development

Biography unavailable

1 / 9